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RESPONSE BIAS AMONG LIKELY CLINICAL 
TRIAL PARTICIPANTS
McDonnell DD, Donohue JA
Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVE: To understand the demographic, attitudi-
nal, behavioral, and clinical characteristics of people who
are likely to participate in clinical trials. METHODS:
Analyses were based on a 12-page questionnaire mailed
to U.S. adults in 2000. A total of 21,986 responses were
received. Respondents were nationally representative
based on gender, age, race, and geographic region; results
were subsequently weighted and projected to the U.S.
population. Participants were asked if they had ever par-
ticipated in a clinical trial and whether they would ever
consider participating in one. RESULTS: Among those
who never participated in a clinical trial, 33% said they
would strongly consider participating in the future. This
group differed in some dramatic ways from the 26% who
said they would definitely not consider participating in a
clinical trial. For example, those who would participate
were more likely to be female (55% v. 49%), younger
(43 v. 47 years), and white (77% v. 70%). Behaviorally,
likely participants were more likely to drink alcohol
(64% v. 55%), smoke (27% v. 22%), visit physicians
(4.0 v. 3.6 visits in six months), and use the internet for
health care information (13% v. 6%). Attitudinally,
those willing to participate were more likely to harbor al-
ternative health care attitudes (e.g., “would try acupunc-
ture” 38% v. 17%) and less likely to be satisfied with
their current medical care (39% v. 47%). Clinically, they
were more likely to be diagnosed with a range of comor-
bid medical conditions such as depression (15% v. 6%),
migraines (16% v. 8%), and nasal allergies (32% v.
21%). CONCLUSION: People who are likely to partici-
pate in clinical trials look, think, and behave differently
than those who are not likely to participate. Trail design
and analysis should consider these differences and their
possible impact on clinical, economic, and humanistic
outcomes.
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CAN UNIT COSTS BE COMPARED ACROSS 
WESTERN EUROPEAN COUNTRIES?
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OBJECTIVE:
 
 It is well documented that resource con-
sumption and costs vary across settings. Unit costs can
also vary. Using consistent cost-finding methods across
and within five Western European (WE) countries unit
costs of cardiovascular procedures were compared to ex-
amine the degree and impact of variation. METHODS:
Unit cost data were collected from fee schedules, national
averages and selected individual institutions. A bottom-
up costing approach was used in hospitals based upon a
definition of resources consumed for procedures. Hospi-
tal daily rates were calculated from an allocation of over-
head accounts and a basic package of services such as
nursing, housekeeping, dietary and pharmacy services.
Costs were obtained in the local currency and converted
directly to Euros. RESULTS: Unit cost variation was ob-
served within and across countries. UK costs for percuta-
neous transluminal coronary angioplasty (PTCA) in 13
centers ranged between 1380 and 2700 Euros, 0.75–1.5
times the median. Inter-country cost variation for the
same procedure ranged between 1850–4000 Euros, 0.60–
1.3 times the median. Daily hospital general ward rates
vary inter-country between 0.8 and 1.6 times the median,
comparable to within country variation. Physician ambu-
latory visit costs from fee schedules that may not reflect
actual costs were standard within country but varied
across countries (0.5–1.2 times the median of 18 Euros).
When applied to a consistent set of resources, differences
in costs resulted in widely varying cost-effectiveness (CE)
ratios by country. CONCLUSIONS: Obtaining compara-
ble unit costs within countries is difficult. Center-specific
costing is most reliable, but expensive and must be repre-
sentative for submissions to national level health authori-
ties. With standardized costing methods, the differences
observed here cannot be explained by differences in ac-
counting. Extreme care must be taken when transferring
the results of CE analyses between centers, especially be-
tween countries.
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COST-EFFECTIVENESS OF AIRLINE 
DEFIBRILLATORS: IS PEACE OF MIND MORE 
IMPORTANT THAN SAVING LIVES?
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OBJECTIVES: Airline passengers are particularly vulner-
able to the effects of cardiac arrest due to a lack of access
to emergency medical services. To offset this isolation,
airlines are installing automated external defibrillators
(AEDs) on aircraft. Our objective was to measure the
cost-effectiveness of airline AED programs and estimate
their value to the flying public. METHODS: A decision
analytic model was constructed to estimate the clinical
and economic effects of airline AEDs. Inputs were ob-
tained from published data and the FAA. Utility esti-
mates were derived from cardiac arrest survivors. Sensi-
tivity analyses evaluated changes in AED cost and
probability of cardiac arrest. Since AEDs may provide
utility gains through “peace of mind” for passengers not
experiencing a medical event, the impact of this added
passenger confidence was also evaluated. RESULTS:
AEDs on commercial aircraft cost an incremental $5.16
per flight. AED deployment resulted in an estimated ad-
